Global Biopharmaceutical Market, Trends, Size, Growth & Forecast

Imarc

Consulting Services

www.imarcgroup.com

Global Biopharmaceutical Market to Grow at 8% During 2016-2021 With Manufacturers Turning to Untapped Regions

Copyright Š 2016 International Market Analysis Research & Consulting (IMARC). All Rights Reserved

Imarc

About IMARC Group

Report Description

www.imarcgroup.com

The International Market Analysis Research and Consulting Group is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations.

Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Global Biopharmaceutical Market to Grow at 8% During 2016-2021 With Manufacturers Turning to Untapped Regions

In order to expand and diversify their operations outside their core markets, biopharmaceutical giants are trying to penetrate emerging markets by collaborating with local pharmaceutical companies or setting up their manufacturing facilities in these regions.

IMARC’s latest report “Global Biopharmaceutical Market Report & Forecast (2016-2021)� provides an in-depth analysis of the global biopharmaceutical market along with a comprehensive study of market trends, geographical structure, therapeutic structure, competitive structure and market outlook. Biopharmaceuticals are large, complex molecules extracted from biological sources such as yeast, E. coli and mammalian cell cultures. Currently, the applications of biopharmaceuticals are increasing as they have high efficiency, limited generic threat, are target oriented and can be used to treat ailments such as cancers and autoimmune diseases. Biopharmaceuticals also have a higher approval rate compared to small molecule drugs and have a very strong tendency to achieve blockbuster status. According to the report, the global biopharmaceutical market was valued at nearly US$ 160 Billion in 2015, growing at a CAGR of 9% during 2008-2015. The market is expected to grow a CAGR of nearly 8% during 2016-2021 as a result of the rising prevalence of chronic diseases such as diabetes, autoimmune diseases, cancers etc., an ageing global population and a significant number of monoclonal antibodies in the pipeline.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Browse press release: http://www.imarcgroup.com/global-biopharmaceutical-market The report has segmented the market on the basis of key regions. As a result of scientific advancements and research facilities, the biopharmaceutical market is largely concentrated in the United States and Western Europe with the United States representing the world’s largest biopharmaceutical market.

However, the growth rates in these markets are expected to decline as both the government and private insurance providers are likely to apply cost containment measures. Consequently, biopharmaceutical giants are focussing on emerging markets such as China, Brazil, India, Russia, Turkey, South Korea and Mexico in order to expand their business. The huge population of these regions along with rising incomes, expanding health insurance coverage and increasing demand for top-shelf medical treatments is expected to drive the global biopharmaceutical market in these regions.

The report has further segmented this market on the basis of various biopharmaceutical classes.

Recombinant proteins currently represent the biggest segment of the biopharmaceutical market accounting for the majority of the global sales. Recombinant proteins were followed by monoclonal antibodies and purified proteins. Monoclonal antibodies, on the other hand, are expected to be the fastest growing class. The report has further analysed the competitive landscape of this market. Some of the key players included in the report are – Roche, Amgen, Novo Nordisk, AbbVie, Sanofi, Johnson & Johnson, etc.

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form/

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Table of Contents 1. Market Definitions & Research Methodology 2. Analyst Briefing 3. Introduction to Biopharmaceuticals 4. Global Biopharmaceutical Market: Industry Performance 4.1 Market Performance & Forecast 4.1.1 Current Performance (2008-2015) 4.1.2 Market Forecast (2016-2021) 4.2 Market Segmentation by Region 4.2.1 Current Performance (2008-2015) 4.2.2 Market Forecast (2016-2021) 4.3 Market Segmentation by Indication 4.3.1 Autoimmune Diseases 4.3.2 Oncology 4.3.3 Metabolic Disorders 4.3.4 Others 4.4 Market Segmentation by Class 4.4.1 Recombinant Proteins 4.4.1.1 Current Performance (2008-2015) 4.4.1.2 Market Forecast (2016-2021) 4.4.2 Monoclonal Antibodies 4.4.2.1 Current Performance (2008-2015)

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

4.4.2.2 Market Forecast (2016-2021) 4.4.3 Purified Proteins 4.4.3.1 Current Performance (2008-2015) 4.4.3.2 Market Forecast (2016-2021) 4.5 Competitive Landscape 4.5.1 Top Biopharmaceutical Players 4.5.1.1 Roche 4.5.1.2 Amgen 4.5.1.3 Novo Nordisk 4.5.1.4 AbbVie 4.5.1.5 Sanofi 4.5.2 Top Biopharmaceutical Drugs 4.5.2.1 Humira 4.5.2.2 Remicade 4.5.2.3 Rituxan 4.5.2.4 Enbrel 4.5.2.5 Lantus 5. North America 5.1 US 5.1.1 Market Performance (2008-2015) 5.1.2 Market Segmentation by Class 5.1.2.1 Recombinant Proteins 5.1.2.2 Monoclonal Antibodies

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

5.1.2.3 Purified Proteins 5.1.3 Performance of Top Players 5.1.4 Market Forecast (2016-2021) 5.2 Canada 5.2.1 Market Performance (2008-2015) 5.2.2 Market Segmentation by Class 5.2.2.1 Recombinant Proteins 5.2.2.2 Monoclonal Antibodies 5.2.3 Performance of Top Players 5.2.4 Market Forecast (2016-2021) 6. Latin America 6.1 Mexico 6.1.1 Market Performance (2008-2015) 6.1.2 Market Segmentation by Class 6.1.2.1 Recombinant Proteins 6.1.2.2 Monoclonal Antibodies 6.1.2.3 Purified Proteins 6.1.3 Performance of Top Players 6.1.4 Market Forecast (2016-2021) 6.2 Brazil 6.2.1 Market Performance (2008-2015) 6.2.2 Market Segmentation by Class 6.2.2.1 Recombinant Proteins

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

6.2.2.2 Monoclonal Antibodies 6.2.2.3 Purified Proteins 6.2.3 Performance of Top Players 6.2.4 Market Forecast (2016-2021) 6.3 Argentina 6.3.1 Market Performance (2008-2015) 6.3.2 Market Segmentation by Class 6.3.2.1 Recombinant Proteins 6.3.2.2 Monoclonal Antibodies 6.3.2.3 Purified Proteins 6.3.3 Performance of Top Players 6.3.4 Market Forecast (2016-2021) 7. Europe 7.1 Germany 7.1.1 Market Performance (2008-2015) 7.1.2 Market Segmentation by Class 7.1.2.1 Recombinant Proteins 7.1.2.2 Monoclonal Antibodies 7.1.2.3 Purified Proteins 7.1.3 Performance of Top Players 7.1.4 Market Forecast (2016-2021) 7.2 France 7.2.1 Market Performance (2008-2015)

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

7.2.2 Market Segmentation by Class 7.2.2.1 Recombinant Proteins 7.2.2.2 Monoclonal Antibodies 7.2.2.3 Purified Proteins 7.2.3 Performance of Top Players 7.2.4 Market Forecast (2016-2021) 7.3 Italy 7.3.1 Market Performance (2008-2015) 7.3.2 Market Segmentation by Class 7.3.2.1 Recombinant Proteins 7.3.2.2 Monoclonal Antibodies 7.3.2.3 Purified Proteins 7.3.3 Performance of Top Players 7.3.4 Market Forecast (2016-2021) 7.4 Spain 7.4.1 Market Performance (2008-2015) 7.4.2 Market Segmentation by Class 7.4.2.1 Recombinant Proteins 7.4.2.2 Monoclonal Antibodies 8.4.2.3 Purified Proteins 7.4.3 Performance of Top Players 7.4.4 Market Forecast (2016-2021) 7.5 UK

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

7.5.1 Market Performance (2008-2015) 7.5.2 Market Segmentation by Class 7.5.2.1 Recombinant Proteins 7.5.2.2 Monoclonal Antibodies 7.5.2.3 Purified Proteins 7.5.3 Performance of Top Players 7.5.4 Market Forecast (2016-2021) 7.6 Russia 7.6.1 Market Performance (2008-2015) 7.6.2 Market Segmentation by Class 7.6.2.1 Recombinant Proteins 7.6.2.2 Monoclonal Antibodies 7.6.2.3 Purified Proteins 7.6.3 Performance of Top Players 7.6.4 Market Forecast(2016-2021) 7.7 Turkey 7.7.1 Market Performance (2008-2015) 7.7.2 Market Segmentation by Class 7.7.2.1 Recombinant Proteins 7.7.2.2 Monoclonal Antibodies 7.7.2.3 Purified Proteins 7.7.3 Performance of Top Players 7.7.4 Market Forecast (2016-2021)

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

8. Asia Pacific 8.1 Japan 8.1.1 Market Performance (2008-2015) 8.1.2 Market Segmentation by Class 8.1.2.1 Recombinant Proteins 8.1.2.2 Monoclonal Antibodies 8.1.2.3 Purified Proteins 8.1.3 Performance of Top Players 8.1.4 Market Forecast (2016-2021) 8.2 China 8.2.1 Market Performance (2008-2015) 8.2.2 Market Segmentation by Class 8.2.2.1 Recombinant Proteins 8.2.2.2 Monoclonal Antibodies 8.2.2.3 Purified Proteins 8.2.3 Performance of Top Players 8.2.4 Market Forecast (2016-2021) 8.3 Australia 8.3.1 Market Performance (2008-2015) 8.3.2 Market Segmentation by Class 8.3.2.1 Recombinant Proteins 8.3.2.2 Monoclonal Antibodies 8.3.2.3 Purified Proteins

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

8.3.3 Performance of Top Players 8.3.4 Market Forecast (2016-2021) 8.4 South Korea 8.4.1 Market Performance (2008-2015) 8.4.2 Market Segmentation by Class 8.4.2.1 Recombinant Proteins 8.4.2.2 Monoclonal Antibodies 8.4.2.3 Purified Proteins 8.4.3 Performance of Top Players 8.4.4 Market Forecast (2016-2021) 8.6 India 8.6.1 Market Performance (2008-2015) 8.6.2 Market Segmentation by Class 8.6.2.1 Recombinant Proteins 8.6.2.2 Monoclonal Antibodies 8.6.2.3 Purified Proteins 8.6.3 Performance of Top Players 8.6.4 Market Forecast (2016-2021) 8.6.5 Market Performance (2008-2015) 8.6.6 Market Segmentation by Class 8.6.6.1 Recombinant Proteins 8.6.6.2 Monoclonal Antibodies 8.6.7 Performance of Top Players

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

8.6.8 Market Forecast (2016-2021) 9. Global Biopharmaceutical Market: Industry Analysis 9.1 Strengths 9.1.1 High Efficacy and Target Oriented Attack 9.1.2 Strong Potential to Achieve Blockbuster Status 9.1.3 Limited Generic Threat 9.1.4 High Approval Success Rates 9.2 Weaknesses 9.2.1 Inconvenient Drug Delivery 9.2.2 Short Half Lives 9.2.3 Second Line of Therapy 9.2.4 High Cost of Therapy 9.2.5 Incidence of Unfavorable Side Effects 9.3 Opportunities 9.3.1 Diseases with High Unmet Needs 9.3.2 Approval into Additional Indications 9.3.3 Emerging Markets 9.3.4 New Approvals and a Strong Pipeline 9.4 Threats 9.4.1 Biopharmaceutical Drug Development is a Very Risky Venture 9.4.2 Biosimilars 9.4.3 Limited and Conditional Reimbursement 9.4.4 Uncertainties in the Economic Environment

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia: Email: apac@imarcgroup.com Phone: +91-120-415-5099

IMARC Group North America: Email: america@imarcgroup.com Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa: Email: ema@imarcgroup.com Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/biotechnology-industry

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Š 2016 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing.

International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

http://www.imarcgroup.com Stay With Us:

TELEPHONE: +91-120-4155099 E-MAIL: sales@imarcgroup.com